Changes to be made to the Prescribed List (Jersey) as at 1 October 2007.

Information about the publication of Ministerial Decisions

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision
providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made (13/09/2007) regarding: Changes to be made to the Prescribed List (Jersey) as at 1 October 2007.

Subject:	Changes to be made to the Prescribed List (Jersey) as at 1 October 2007
Decision Reference:	MD-S-2007-0058		Exempt clause(s):	N/A
Type of Report: (oral or written)	Written		Person Giving Report (if oral):	N/A
Telephone or e-mail Meeting?	N/A		Report File ref:	2/2/4
Written report – Title	Prescribed List (Jersey) 1 October 2007
Written report – Author (name and job title)	Rosie Goulding Policy Principal
Decision(s): To approve changes to the Prescribed List (Jersey) as recommended by the Pharmaceutical Benefits Advisory Committee from the meeting held on the 10 July 2007. To be included: Omega-3-acid ethyl esters capsules 1g (Omacor - Solvay) (green classification) Rosuvastatin 5mg, 10mg, 20mg (green classification) Solifenacin tablets 5mg, 10mg (green classification) Additional green items Please refer to the attached list of 435 items To be included as amber items (subject to shared care protocols) 6-mercaptopurine Inflammatory bowel disease Atypical neuroleptics Schizophrenia (amisulpride, olanzapine, quetiapine) Azathioprine Rheumatoid arthritis and connective tissue disorders Cabergoline Parkinson’s Disease Ciclosporin Rheumatoid arthritis, autoimmune disease, renal transplant Ciclophosphamide Rheumatoid arthritis, autoimmune disease Valproate semisodium Acute mania Donepezil Alzheimer’s disease Entacapone Parkinson’s disease Galantamine Alzheimer’s disease Lithium Bipolar illness Memantine Alzheimer’s disease Methotrexate Rheumatoid arthritis, psoriasis Pergolide Parkinson’s disease Pramipexole Parkinson’s disease Ropinirole Parkinson’s disease Sirolimus Renal transplant Tacrolimus Organ transplant To give notice that the following items will be deleted from the 1 January 2008 Phenytoin tablets (non-proprietary) 50mg; 100mg Atorvastatin tablets 10mg; 20mg; 40mg Ramipril tablet formulation (non-proprietary) all strengths
Reason(s) for decision: The Pharmaceutical Benefits Advisory Committee met on 10 July 2007. They have provided the Department with significant recommended changes to the Prescribed List (Jersey) to become effective from 1 October 2007. These changes include the implementation of several shared care arrangements and classification of medicines to promote effective care across different health settings. Recent and extensive work has been undertaken to move long term prescribing of medicines from hospital specialists to GPs and develop a single Island formulary. This change allows the seamless transfer of patient treatment from the secondary care sector to general practice. It is also a means of communicating relevant clinical details between consultant and GP. Shared care prescribing agreements and governance arrangements are used to combine the best of both primary and secondary care for the benefit of the patient. This development will result in an additional £1.3 million (approximate) cost to the Health Insurance fund. The fund has sufficient resources to fund this development The Pharmaceutical Benefits Advisory Committee will consider the impact of adding each new drug to the List on an individual basis at the time of application. The Committee’s aim is to ensure that General Practitioners have the choice available to them of modern, safe and effective medicine. Therefore three categories of medicine are now defined: Green items – These medicines are available for all General Practitioners to prescribe Amber items – These medicines must be initiated in the hospital but long term prescribing may be transferred to primary care within a shared- care framework Red items – these medicines will only be available in the hospital environment The Committee has provided recommendations for new formulations to be included on the Prescribed List (Jersey) from 1 October 2007.
Action required: The Minister is asked to approve the recommendation made by the Pharmaceutical Benefits Advisory Committee.
Signature: Senator P.F. Routier - Minister		Date of Decision: